Shandong Xinhua Pharmaceutical Co (FRA:XIN) Cyclically Adjusted Revenue per Share: €0.48 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:XIN Shandong Xinhua Pharmaceutical Co Ltd FRA:XIN
57 GF Score
Price €0.65
GF Value €0.82
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Shandong Xinhua Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Shandong Xinhua Pharmaceutical Co FRA:XIN -2.26% 57 Cyclically Adjusted Revenue per Share is €0.48 as of Mar. 2026. GuruFocus rates FRA:XIN with a GF Score™ of 57/100 and a GF Value™ of €0.82 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Shandong Xinhua Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was €0.435. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.48 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Shandong Xinhua Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 7.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 7.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Shandong Xinhua Pharmaceutical Co was 9.70% per year. The lowest was 5.70% per year. And the median was 8.00% per year.

As of today (2026-07-26), Shandong Xinhua Pharmaceutical Co's current stock price is €0.65. Shandong Xinhua Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €0.48. Shandong Xinhua Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 1.35.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Shandong Xinhua Pharmaceutical Co was 5.36. The lowest was 0.85. And the median was 1.56.


Shandong Xinhua Pharmaceutical Co  (FRA:XIN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Shandong Xinhua Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.65/0.48
=1.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Shandong Xinhua Pharmaceutical Co was 5.36. The lowest was 0.85. And the median was 1.56.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Shandong Xinhua Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Shandong Xinhua Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Shandong Xinhua Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Xinhua Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Shandong Xinhua Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 0.27 0.29 0.43 0.47

Shandong Xinhua Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.43 0.50 0.47 0.48

FRA:XIN vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Xinhua Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shandong Xinhua Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shandong Xinhua Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Shandong Xinhua Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


FRA:XIN
57GF Score
Shandong Xinhua Pharmaceutical Co Ltd FRA:XIN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shandong Xinhua Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Shandong Xinhua Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.435/116.3033*116.3033
=0.435

Current CPI (Mar. 2026) = 116.3033.

Shandong Xinhua Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.252 101.400 0.289
201609 0.209 102.400 0.237
201612 0.231 102.600 0.262
201703 0.288 103.200 0.325
201706 0.242 103.100 0.273
201709 0.220 104.100 0.246
201712 0.228 104.500 0.254
201803 0.296 105.300 0.327
201806 0.272 104.900 0.302
201809 0.250 106.600 0.273
201812 0.265 106.500 0.289
201903 0.339 107.700 0.366
201906 0.315 107.700 0.340
201909 0.272 109.800 0.288
201912 0.234 111.200 0.245
202003 0.357 112.300 0.370
202006 0.322 110.400 0.339
202009 0.274 111.700 0.285
202012 0.263 111.500 0.274
202103 0.364 112.662 0.376
202106 0.369 111.769 0.384
202109 0.281 112.215 0.291
202112 0.358 113.108 0.368
202203 0.411 114.335 0.418
202206 0.394 114.558 0.400
202209 0.365 115.339 0.368
202212 0.399 115.116 0.403
202303 0.519 115.116 0.524
202306 0.377 114.558 0.383
202309 0.345 115.339 0.348
202312 0.296 114.781 0.300
202403 0.468 115.227 0.472
202406 0.401 114.781 0.406
202409 0.362 115.785 0.364
202412 0.324 114.893 0.328
202503 0.415 115.116 0.419
202506 0.410 114.907 0.415
202509 0.374 115.471 0.377
202512 0.353 115.832 0.354
202603 0.435 116.303 0.435

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.48 mean?
Shandong Xinhua Pharmaceutical Co (FRA:XIN) has a Cyclically Adjusted Revenue per Share of €0.48 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Shandong Xinhua Pharmaceutical Co and its competitors.
Is Shandong Xinhua Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Shandong Xinhua Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is €0.48. Overall, Shandong Xinhua Pharmaceutical Co has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Xinhua Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Shandong Xinhua Pharmaceutical Co's Cyclically Adjusted Revenue per Share of €0.48 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Shandong Xinhua Pharmaceutical Co and its competitors. Shandong Xinhua Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is €0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Xinhua Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Xinhua Pharmaceutical Co (FRA:XIN) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.82, compared to a current price of €0.65 — trading 20.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.48. Shandong Xinhua Pharmaceutical Co's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Shandong Xinhua Pharmaceutical Co (FRA:XIN), the current Cyclically Adjusted Revenue per Share is €0.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shandong Xinhua Pharmaceutical Co (FRA:XIN) Overvalued in 2026?

Based on GuruFocus' analysis, Shandong Xinhua Pharmaceutical Co stock appears to be undervalued. The current stock price of €0.65 is trading 20.7% below its estimated GF Value™ of €0.82. GuruFocus considers Shandong Xinhua Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for FRA:XIN:

  • Cyclically Adjusted Revenue per Share: €0.48
  • GF Value™: €0.82 vs. price of €0.65 (20.7% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the FRA:XIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shandong Xinhua Pharmaceutical Co Business Description

Other Exchanges 00719:Hong Kong000756:China
Address No. 1 Lutai Avenue, Hi-tech Industry Development Zone, Zibo, Shandong, CHN, 255086
Shandong Xinhua Pharmaceutical Co Ltd is a pharmaceutical products manufacturer based in China. It operates various segments namely Chemical raw materials, Preparations, Pharmaceutical intermediates and other products. The company is mainly engaged in the business of development, manufacture and sale of bulk pharmaceuticals, preparations and chemical products.
57GF Score

Get the complete analysis for FRA:XIN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.65
Price
€0.82
GF Value